Teva Pharmaceutical Industries Ltd. is acquiring privately-held Taiyo Pharmaceutical Industry, Japan’s third largest generic pharmaceutical company for $460 million.
Taiyo has one of the most comprehensive generic product portfolios in the Japanese market and has a strong presence in all major distribution channels in Japan.
Japan is the second largest pharmaceutical market in the world, valued at $96 billion in 2010. The Japanese government has expressed its intention to increase generic penetration to 30% by 2012. Teva is is headquartered in Israel and is the world’s largest generic drug maker with a direct presence in about 60 countries.
Discover more from
Subscribe to get the latest posts sent to your email.
